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Abstract
High mobility group protein A1a (HMGA1a) acts as an architectural transcription factor and influences a diverse array of
normal biological processes. It binds AT-rich sequences, and previous reports have demonstrated HMGA1a binding to the
authentic promoters of various genes. However, the precise sequences that HMGA1a binds to remain to be clarified.
Therefore, in this study, we searched for the sequences with the highest affinity for human HMGA1a using an existing SELEX
method, and then compared the identified sequences with known human promoter sequences. Based on our results, we
propose the sequences ‘‘-(G/A)-G-(A/T)-(A/T)-A-T-T-T-’’ as HMGA1a-binding candidate sequences. Furthermore, these
candidate sequences bound native human HMGA1a from SK-N-SH cells. When candidate sequences were analyzed by
performing FASTAs against all known human promoter sequences, 500–900 sequences were hit by each one. Some of the
extracted genes have already been proven or suggested as HMGA1a-binding promoters. The candidate sequences
presented here represent important information for research into the various roles of HMGA1a, including cell differentiation,
death, growth, proliferation, and the pathogenesis of cancer.
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Introduction
High mobility group protein A1a (HMGA1a) participates in a
wide variety of nuclear processes acting as an architectural
transcription factor regulating the expression of numerous genes
[1–3]. This protein influences a diverse array of normal biological
processes, including cell differentiation, death, growth and
proliferation, and is involved in the pathogenesis of cancer via
protein–protein and DNA–protein interactions [1–3]. Therefore,
HMGA1a protein has been described as the central ‘hub’ of
nuclear function [2].
HMGA1a binds AT-rich sequences via its own AT-hook, and
functions in a variety of ways [1–3]. Many previous reports have
demonstrated HMGA1a binding to the authentic promoters of various
genes (for example, human KIT Ligand (hKL) [4], Xeroderma
pigmentosum complementation group A [5], Cox2 [6,7], interferon-b
[8], interleukin-10 [9] and -4 [10], iNos/Nos2 [11], c-Fos and SM22a
[12]) using DNase I protection assays and/or electrophoretic mobility
shift assays (EMSAs). Furthermore, several HMGA1a-regulating genes
and pathways have been suggested by microarray analyses [13].
However, although AT-rich sequences exist within authentic gene
promoters, their affinity for HMGA1a varies from strong to weak to
none at all; even within the same promoter, AT-rich sequences can
have vastly differing affinities for HMGA1a [8,14]. It remains to be
clarified exactly which sequences HMGA1a binds to, and whether and
how co-factors, structures, and the existence of binding regions on the
surface of the DNA-protein complex influence HMGA1a-DNA
binding. Therefore, using an existing SELEX method to study all
known human promoter sequences, we searched for the sequences
with the highest affinity for human HMGA1a.
Results and Discussion
Determination of HMGA1a Recognition Candidate DNA
Sequences in Humans
The ratios of the four bases in the synthesized random
sequences used in this research, which were placed between T7
sequences, were almost uniform, as a result of a direct sequencing
(Figure 1a). When these random sequences of DNA were
analyzed using the SELEX method with E. coli.-expressed
recombinant HMGA1a [15], the ratio of the four bases became
AT-rich, with the frequencies of A and T significantly higher (by
about 40%) than the frequencies of G and C (Figure 1b). This
result shows that the SELEX system selects specific bases; in the
case here, and as reported [1], AT-rich sequences. The relative
levels of bases in regions assumed to be recognition sequences was
as follows: C,G%,A/T (Figures S1 and 1c). The bases A and T
were twice as common, or more, as the bases C and G (Figures
S1 and1c). We propose the sequences ‘‘-(G/A)-G-(A/T)-(A/T)-A-
T-T-T-’’ as HMGA1a-binding candidate sequences (Figure 1d).
Besides being AT-rich, the inclusion of a GG sequence
immediately before the AT-rich sequence is interesting. Indeed,
the existence of such a GG sequence in authentic promoters has
been reported [3,8,10].
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Native HMGA1a undergoes various post-translational modifi-
cations [1,2]. Therefore, binding of endogenous HMGA1a from
human cell nuclear extracts to these candidate sequences was
examined by EMSAs (Figures 2A and 2B). Previous reports have
demonstrated that HMGA1a expression is significantly increased
by hypoxia stimuli in human neuroblastoma SK-N-SH cells, but
not in HEK293T or HeLa cells [16,17]. Using the system
described in those reports, binding that was weak under normoxia
(Figure 2A, lane 1) became much stronger following hypoxic
Figure 1. HMGA1a Recognition Candidate DNA Sequences by SELEX. Ratio of bases in synthetic DNA sequences before (A) and after (B)
SELEX assays. (C) Ratio of bases in regions of candidate DNA sequences after SELEX assays. (D) Candidate HMGA1a binding sequences are shown.
doi:10.1371/journal.pone.0008004.g001
Figure 2. Effects of endogenous HMGA1a on binding to the candidate sequences by EMSA. (A) Radiography of EMSA using nuclear
extracts obtained from human neuroblastoma SK-N-SH cells under normoxic (lane 1) or hypoxic (lane 2) conditions, or hypoxia (HMGA1a removal:
lane 3). (B) Densitometric quantitative data from (A) shown as the % of the levels in normoxia.
doi:10.1371/journal.pone.0008004.g002
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was prevented by inactivation of HMGA1a in the nuclear extracts
using an antibody against it (Figures. 2A and 2B). Therefore, our
advocated candidate sequence bound native human HMGA1a
from SK-N-SH cells.
The Candidate Sequences in All Known Human
Promoters by FASTA Analysis
There were eight candidate sequences in total: GGAAATTT,
GGATATTT, GGTAATTT, GGTTATTT, AGAAATTT, AG-
ATATTT, AGTAATTT, and AGTTATTT. When all known
human promoter sequences were analyzed by performing a
FASTA on each sequence, 500–900 sequences were hit by each
one (Table S1). It is interesting that two or more candidate
sequences were found in many of the extracted gene promoters,
while the vast majority of human promoter sequences were not hit
by any of the candidate sequences (Table 1). This strongly suggests
that these candidate sequences are genuine. Moreover, it is also
interesting that some of the genes that have already been proven
or suggested to have promoters that bind HMGA1a were
extracted (Table 2).
The functions of HMGA1a are diverse and it is known to have a
role in disease appearance; thus, the possibility of its becoming a
target of treatments has been suggested ([28], Table 3). That is, the
candidate sequences proposed by this study may be a blocker of
the transcription of cancer-related genes (Table 3), as decoy
DNAs. We also reported that a decoy RNA of a specific
HMGA1a-binding sequence prevents cell death [29]. In conclu-
sion, the candidate sequences presented here represent important
information for research into the various roles of HMGA1a.
Materials and Methods
DNA Selection Assay In Vitro (SELEX)
A synthesized DNA (1 pmol) [59-GGTGATCAGATTCT-
GATCCA (N31) TGAAGCTTGGATCCGTCGC-39] molecule
containing a 31-nucleotide random sequence (20.7% A, 22.7% C,
31.5% T, 25.1% G by direct sequencing of 16 clones) was
amplified (seven cycles) by PCR, followed by incubation with E.
coli.-expressed rHMGA1a in incubation buffer [16] for 30 min at
25uC. The reaction solution was then subjected to immunopre-
cipitation with an antibody against HMGA1, followed by
amplification (seven cycles) by PCR. The PCR products were
cloned into a pGEM-T vector and analyzed by direct sequencing.
Gel electrophoresis Mobility Shift Assay (EMSA)
After determining the protein content in the nuclear extracts, an
aliquot containing 5 mg of protein was incubated with 1 mgo fp o l y -
dIdC in incubation buffer; then, 1 mgo f
32P-labeled-DNA probe (gcg-
G/A-G-T/A-A/T-ATTTcgc) was added in a total volume of 50 ml,
Table 1. Percentage of repetition in other candidate sequences on the hit gene promoters retrieved using each candidate
sequence.
(a)
Retrieval candidate
sequences 0 (b) 1 2 3 4 5 6 7 (c)
Number of
total hits
GGAAATTT 5.8% 13.3% 20.1% 24.6% 22.0% 10.4% 3.4% 0.48% 618
GGTAATTT 4.9% 14.1% 20.4% 23.5% 20.1% 12.3% 4.2% 0.54% 553
GGATATTT 5.9% 13.2% 21.5% 23.2% 19.9% 11.2% 4.5% 0.59% 508
GGTTATTT 6.4% 13.4% 19.5% 23.2% 21.9% 11.4% 3.5% 0.55% 543
AGTTATTT 6.9% 11.9% 24.5% 22.9% 20.0% 10.0% 3.5% 0.38% 781
AGAAATTT 7.0% 15.0% 21.8% 25.1% 18.2% 9.8% 2.8% 0.35% 859
AGATATTT 5.2% 16.6% 20.1% 23.6% 19.7% 11.3% 3.1% 0.39% 767
AGTAATTT 5.4% 12.7% 20.0% 26.6% 19.1% 12.3% 3.5% 0.45% 661
(a): Number of repetition with other candidate sequences. (b): Only the retrieval sequence. (c): All candidate sequences.
doi:10.1371/journal.pone.0008004.t001
Table 2. List of genes that have already been proven or
suggested to have promoters that bind HMGA1a.
No. Promoters (a) (b) (c) (d) (e) (f) (g) (h) Ref.
EP64001 rag-1 + 2 ++++ ++[19]
EP07113 interferon -gamma
(IFNc)
++22++ +2 [18]
EP16050 HMG-CoA reductase + 2 ++2 ++ 2 [13]
EP11141 estrogen receptor +++2 ++ 22[13]
EP73494 CCNB2 (coding for
the cyclin B2 protein)
22+ 2 ++ ++[23]
EP11104 b-globin 2 ++2 ++ +2 [26]
EP07112 interferon -beta (IFNb) + 222++ +2 [8]
EP73108 CD44 22++++ 22[22]
EP07121 MHCII HLA-DRA 2 ++2 + 22 + [27]
EP11145 FOS + 2 + 222 + 2 [12]
EP47012 Inducible Nitric Oxide
Synthase (iNOS)
++2222 2+ [11]
EP59011 elk-1 222+ 22 ++[13]
EP07114 interleukin-2 (IL-2) 2 ++222 22[20]
EP15045 ErbB2 (HER2/neu) + 222+ 22 2 [25]
EP15046 ErbB2 (HER2/neu) + 222+ 22 2 [25]
EP25083 rhodopsin 22++22 22[21]
EP73053 crystallin, alpha B
(CRYAB)
2 + 2222 22[24]
EP26038 interleukin-4 (IL-4) 222222 + 2 [10]
(a): GGAAATTT, (b): GGTAATTT, (c): GGATATTT, (d): GGTTATTT, (e): AGTTATTT, (f):
AGAAATTT, (g): AGATATTT, (h): AGTAATTT.
doi:10.1371/journal.pone.0008004.t002
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25uC. Bound and free probes were separated by 4% polyacrylamide
gel electrophoresis in buffer (pH 8.5) containing 50 mM Tris, 0.38 M
glycine and 2 mM EDTA at a constant voltage of 11 V/cm for 1.5 h
at 4uC. Dried gels were analyzed by autoradiography.
Supporting Information
Figure S1 Direct sequencing data after SELEX assay.
Found at: doi:10.1371/journal.pone.0008004.s001 (3.58 MB TIF)
Table S1 Hit gene promoters of each candidate gene.
Found at: doi:10.1371/journal.pone.0008004.s002 (0.32 MB
PDF)
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